Literature DB >> 409413

Comparison of two dosage schedules of gold salts in the treatment of rheumatoid arthritis. Relationship of serum gold levels to therapeutic response.

J T Sharp, M D Lidsky, J Duffy, H K Thompson, B D Person, A F Masri, A A Andrianakos.   

Abstract

Two doses of gold sodium thiomalate were compared for their effect on rheumatoid arthritis. Thirty-seven patients with active disease for longer than 6 months were treated with 25 mg of gold sodium thiomalate for an average of 29.6 weeks, then at biweekly or monthly intervals to complete 2 years of treatment. Thirty-eight patients were given more than twice as much gold salt at the same intervals on a flexible dose schedule that produced serum gold levels which averaged 332 microgram/dl during the weekly injection phase. No differences were observed in the therapeutic responses of the two groups. Therefore the minimal dose of gold sodium thiomalate required to induce a response in rheumatoid arthritis is 25 mg or less per week. Serum gold levels in the steady state varied between 95 and 386 microgram/dl and were not related to response. Serum half-life for gold was calculated for patients who had an excellent response and for those who were treatment failures. The rate at which gold disappeared from serum was not related to therapeutic responses.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 409413     DOI: 10.1002/art.1780200604

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

1.  Binding of sodium aurothiomalate to human serum albumin in vitro at physiological conditions.

Authors:  S M Pedersen
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

2.  Aurothioglucose overdosage in five patients with rheumatoid arthritis.

Authors:  I Rubinstein; P Langevitz; M Pras
Journal:  Clin Rheumatol       Date:  1987-12       Impact factor: 2.980

3.  Oral gold for rheumatoid arthritis.

Authors:  V Wright
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-06

4.  Gold binding to blood cells and serum proteins during chrysotherapy.

Authors:  R J van de Stadt; B Abbo-Tilstra
Journal:  Ann Rheum Dis       Date:  1980-02       Impact factor: 19.103

Review 5.  Antirheumatic drugs: clinical pharmacology and therapeutic use.

Authors:  G L Craig; W W Buchanan
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

Review 6.  Have traditional DMARDs had their day? Effectiveness of parenteral gold compared to biologic agents.

Authors:  Rolf Rau
Journal:  Clin Rheumatol       Date:  2004-07-24       Impact factor: 2.980

7.  Blood gold concentrations in children with juvenile rheumatoid arthritis undergoing long-term oral gold therapy.

Authors:  E H Giannini; E J Brewer; D A Person
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

8.  Radiological progression in rheumatoid arthritis: how many patients are required in a treatment trial to test disease modification?

Authors:  J T Sharp; F Wolfe; M Corbett; H Isomaki; D M Mitchell; D E Furst; J Sibley; M Shipley
Journal:  Ann Rheum Dis       Date:  1993-05       Impact factor: 19.103

9.  Differential effects of therapeutic regimens on specific classes of rheumatoid factor.

Authors:  R M Pope; J Lessard; E Nunnery
Journal:  Ann Rheum Dis       Date:  1986-03       Impact factor: 19.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.